ArticleBMC gastroenterology2026

Efficacy and safety of dual biologics or combination therapy with JAK inhibitors in refractory inflammatory bowel disease: a retrospective single-center real-world study from China.

Jiao-Jiao Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.